Thetis Pharmaceuticals reports it has received a Fast-Track Small Business Innovation Research Grant from the National Institutes of Health (for development of an innovative new therapy, TP-352, for non-alcoholic steatohepatitis, a chronic fatty liver disorder affecting 18 million patients in the U.S.
“With this grant funding, Thetis has raised $7 million of non-dilutive NIH grant funding across our portfolio of gastrointestinal drug candidates,” stated Gary Mathias, Thetis’ CEO. more